Literature DB >> 9506992

The epidermal growth factor receptor associates with and recruits phosphatidylinositol 3-kinase to the platelet-derived growth factor beta receptor.

A A Habib1, T Högnason, J Ren, K Stefánsson, R R Ratan.   

Abstract

Receptor tyrosine kinases are classified into subfamilies, which are believed to function independently, with heterodimerization occurring only within the same subfamily. In this study, we present evidence suggesting a direct interaction between the epidermal growth factor (EGF) receptor (EGFR) and the platelet-derived growth factor beta (PDGFbeta) receptor (PDGFbetaR), members of different receptor tyrosine kinase subfamilies. We find that the addition of EGF to COS-7 cells and to human foreskin Hs27 fibroblasts results in a rapid tyrosine phosphorylation of the PDGFbetaR and results in the recruitment of phosphatidylinositol 3-kinase to the PDGFbetaR. In R1hER cells, which overexpress the EGFR, we find ligand-independent tyrosine phosphorylation of the PDGFbetaR and the constitutive binding of a substantial amount of PI-3 kinase activity to it, mimicking the effect of ligand in untransfected cells. In support of the possibility that this may be a direct interaction, we show that the two receptors can be coimmunoprecipitated from untransfected Hs27 fibroblasts and from COS-7 cells. This association can be reconstituted by introducing the two receptors into 293 EBNA cells. The EGFR/PDGFbetaR association is ligand-independent in all cell lines tested. We also demonstrate that the fraction of PDGFbetaR bound to the EGFR in R1hER cells undergoes an EGF-induced mobility shift on Western blots indicative of phosphorylation. Our findings indicate that direct interactions between receptor tyrosine kinases classified under different subfamilies may be more widespread than previously believed.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9506992     DOI: 10.1074/jbc.273.12.6885

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  14 in total

Review 1.  NF-kappaB in pancreatic cancer.

Authors:  Guido M Sclabas; Shuichi Fujioka; Christian Schmidt; Douglas B Evans; Paul J Chiao
Journal:  Int J Gastrointest Cancer       Date:  2003

Review 2.  [Pathophysiologic significance of growth factors and new therapeutic concepts in cardiovascular disease].

Authors:  S Rosenkranz; M Böhm; A Kazlauskas
Journal:  Med Klin (Munich)       Date:  1999-09-15

3.  The RTK Interactome: Overview and Perspective on RTK Heterointeractions.

Authors:  Michael D Paul; Kalina Hristova
Journal:  Chem Rev       Date:  2018-12-27       Impact factor: 60.622

4.  EGFR and c-Met Cross Talk in Glioblastoma and Its Regulation by Human Cord Blood Stem Cells.

Authors:  Kiran Kumar Velpula; Venkata Ramesh Dasari; Swapna Asuthkar; Bharathi Gorantla; Andrew J Tsung
Journal:  Transl Oncol       Date:  2012-10-01       Impact factor: 4.243

5.  Role and regulation of PDGFRα signaling in liver development and regeneration.

Authors:  Prince K Awuah; Kari N Nejak-Bowen; Satdarshan P S Monga
Journal:  Am J Pathol       Date:  2013-03-23       Impact factor: 4.307

6.  Restoring apoptosis in pancreatic cancer cells by targeting the nuclear factor-kappaB signaling pathway with the anti-epidermal growth factor antibody IMC-C225.

Authors:  Guido M Sclabas; Shuichi Fujioka; Christian Schmidt; Zhen Fan; Douglas B Evans; Paul J Chiao
Journal:  J Gastrointest Surg       Date:  2003-01       Impact factor: 3.452

7.  The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases.

Authors:  Vinochani Pillay; Layal Allaf; Alexander L Wilding; Jacqui F Donoghue; Naomi W Court; Steve A Greenall; Andrew M Scott; Terrance G Johns
Journal:  Neoplasia       Date:  2009-05       Impact factor: 5.715

Review 8.  Tyrosine kinase signalling in breast cancer. Epidermal growth factor receptor: convergence point for signal integration and diversification.

Authors:  N Prenzel; E Zwick; M Leserer; A Ullrich
Journal:  Breast Cancer Res       Date:  2000-03-25       Impact factor: 6.466

9.  Macitentan inhibits the transforming growth factor-β profibrotic action, blocking the signaling mediated by the ETR/TβRI complex in systemic sclerosis dermal fibroblasts.

Authors:  Paola Cipriani; Paola Di Benedetto; Piero Ruscitti; Daniela Verzella; Mariafausta Fischietti; Francesca Zazzeroni; Vasiliki Liakouli; Francesco Carubbi; Onorina Berardicurti; Edoardo Alesse; Roberto Giacomelli
Journal:  Arthritis Res Ther       Date:  2015-09-10       Impact factor: 5.156

10.  Epidermal Growth Factor Receptor (EGFR) Crosstalks in Liver Cancer.

Authors:  Carmen Berasain; María Ujue Latasa; Raquel Urtasun; Saioa Goñi; María Elizalde; Oihane Garcia-Irigoyen; María Azcona; Jesús Prieto; Matías A Avila
Journal:  Cancers (Basel)       Date:  2011-05-18       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.